EDMONTON, March 31 /CNW/ - Isotechnika Inc. announced today that an independent data monitoring committee (DMC) has met and reviewed the interim data from the ongoing Phase 3 psoriasis (ESSENCE) trial. The review included 24-week data from approximately 50% of the patients enrolled in the trial. Based on their review of the safety and efficacy data, the DMC has not raised any concerns that would require a change to the original study design.
